Guanfacine
Is It Right for You?
A complete guide to Guanfacine — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Guanfacine?
Guanfacine is a selective alpha-2A adrenergic receptor agonist available in two distinct formulations: immediate-release guanfacine (Tenex), historically used for hypertension, and extended-release guanfacine (Intuniv), which is the principal formulation used today for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Extended-release guanfacine is available in tablets of 1 mg, 2 mg, 3 mg, and 4 mg.
Guanfacine is a non-stimulant ADHD medication — a pharmacological class distinct from methylphenidate and amphetamine-based agents. This makes it particularly valuable in patients who cannot tolerate stimulant medications, in whom stimulants are contraindicated (e.g., significant cardiovascular disease, tic disorders, or substance misuse history), or as an adjunct to stimulant therapy when stimulant monotherapy provides insufficient control of ADHD symptoms.
Guanfacine extended-release is a prescription-only medication in the UK. Initiation requires specialist paediatric or ADHD specialist assessment and is subject to NICE guidance on ADHD pharmacological treatment.
What Conditions Is Guanfacine Used For?
Guanfacine is indicated for:
licensed as monotherapy when stimulant medications are not appropriate, or as adjunctive therapy alongside stimulants when stimulant monotherapy is insufficient; Intuniv is specifically licensed for this age group in the UK
used in clinical practice under specialist guidance when stimulants are contraindicated or insufficient in adults with ADHD
guanfacine is one of the preferred non-stimulant options when tic disorders complicate ADHD management, as it does not exacerbate and may improve tic symptoms
the immediate-release formulation has been used for hypertension, though it is rarely used for this indication in contemporary UK practice
Pharmacological treatment with guanfacine should always be part of a multimodal ADHD management strategy that includes psychoeducation, behavioural interventions, school-based support, and family support. Medication alone does not comprehensively address all aspects of ADHD. Regular specialist review of symptom control, side effects, and growth is required throughout treatment.
How Does Guanfacine Work?
Guanfacine's mechanism of action in ADHD is centred on the prefrontal cortex (PFC) — the brain region principally responsible for executive functions including attention, working memory, impulse control, and emotional regulation:
Selective alpha-2A adrenergic receptor agonism: Guanfacine binds selectively and with high affinity to alpha-2A adrenergic receptors in the prefrontal cortex. Unlike clonidine (a less selective alpha-2 agonist), guanfacine's preferential affinity for the alpha-2A subtype — which is densely expressed on PFC pyramidal neurons — produces more targeted cognitive effects with a relatively lower degree of sedation.
Strengthening of PFC network connectivity: Alpha-2A receptor activation on PFC neurons hyperpolarises them through a Gi-protein-mediated mechanism, reducing cyclic AMP levels and opening HCN channels. This paradoxically strengthens the functional connectivity of PFC neural networks by reducing "noise" (non-signal neuronal activity) while preserving and enhancing "signal" (task-relevant activity). The result is improved signal-to-noise ratio in the PFC circuits governing attention, impulse inhibition, and working memory — directly targeting the neurobiological substrate of ADHD.
Central sympatholytic effects: In the brainstem and spinal cord, alpha-2A receptor agonism reduces norepinephrine release from the locus coeruleus, contributing to the sedative, anxiolytic, and blood pressure-lowering effects of guanfacine — which are pharmacologically useful in some contexts but also represent principal adverse effects.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Take at the same time each day — typically in the evening to minimise daytime sedation, though morning dosing is sometimes preferred; follow your specialist's instruction.
Swallow Intuniv tablets whole. Do not crush, chew, or break extended-release tablets — this destroys the release mechanism and produces an immediate high-dose bolus.
Do not take with high-fat meals. High-fat food significantly increases guanfacine absorption (Cmax increases by up to 75% and AUC by approximately 40%), potentially leading to excessive sedation and hypotension; take at a consistent time relative to food.
Never stop guanfacine suddenly. Abrupt discontinuation can cause rebound hypertension, tachycardia, and significant agitation — particularly after prolonged use or at higher doses. Always taper under clinical supervision.
Monitor blood pressure and heart rate at each dose step. Guanfacine lowers both; check before any dose increase and ensure levels are acceptable before escalating.
Side Effects of Guanfacine
Most side effects are mild and resolve on their own. Serious side effects are rare but require immediate medical attention.
- Somnolence and fatigue --- the most frequently reported side effect, particularly during the first 2–4 weeks and after each dose increase; usually improves with time
- Headache
- Abdominal pain and nausea
- Hypotension (low blood pressure) --- including orthostatic hypotension and dizziness on standing
- Bradycardia (slow heart rate)
- Dry mouth
- Irritability or emotional lability --- particularly during the titration phase
- Decreased appetite
- Severe hypotension or syncope --- particularly following dose increases, in dehydrated patients, or when combined with antihypertensive agents; presents as dizziness, near-fainting, or collapse
- Significant bradycardia --- heart rate
- Rebound hypertension --- following abrupt discontinuation; can be clinically significant, particularly at higher doses; always taper gradually
- QT interval prolongation --- guanfacine may prolong the QT interval; avoid in patients with known QT prolongation or on concurrent QT-prolonging medications; baseline and follow-up ECG recommended
- Severe allergic hypersensitivity reactions --- rare
Guanfacine lowers both blood pressure and heart rate through its central sympatholytic mechanism. Blood pressure and pulse must be measured before initiating treatment, before each dose increase, and at regular review appointments. Guanfacine should not be initiated in children with clinically significant cardiac disease, history of syncope, or known QT prolongation without specialist cardiology review.
Drug Interactions
Always disclose all prescription drugs, over-the-counter medicines, vitamins, and supplements to your clinician or pharmacist before starting Guanfacine
additive sedation; avoid concurrent use where possible; advise avoidance of alcohol during treatment.
additive QT prolongation; review all concurrent medications; baseline ECG recommended.
both agents may lower blood pressure; monitor carefully; some evidence of pharmacodynamic interaction.
no clinically significant interaction at standard doses.
Important Warnings
Abrupt discontinuation of guanfacine — particularly from higher doses or after prolonged use — can cause clinically significant rebound hypertension, tachycardia, and agitation. Always taper the dose gradually over at least 1 week under medical supervision.
Blood pressure and heart rate must be assessed at baseline, before each dose increase, and at regular review appointments. Guanfacine should not be initiated in children with clinically significant cardiac disease, history of syncope, or known QT prolongation without specialist cardiology review.
Sedation is common at initiation and with each dose increase. Where sedation is significantly affecting a child's daytime alertness, school performance, or safety, clinical review of timing and dose is required. Evening dosing often reduces daytime somnolence.
High-fat food substantially increases guanfacine exposure from Intuniv tablets. Guanfacine should be taken at a consistent time relative to meals and not immediately following a high-fat meal, to maintain predictable drug levels.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Guanfacine FAQs
Guanfacine is a non-stimulant medication that works by directly modulating alpha-2A adrenergic receptors in the prefrontal cortex, strengthening the neural circuits that govern attention and impulse control. Stimulants work by increasing dopamine and norepinephrine availability across multiple brain regions simultaneously. Guanfacine has a smoother onset, no abuse potential, and does not worsen tics — advantages that make it preferable in specific patient groups — but its onset of full therapeutic effect is slower, typically requiring several weeks of dose titration.
Somnolence is the most common side effect of guanfacine and is particularly prominent in the first 2–4 weeks and after each dose increase. In most children, it improves significantly as tolerance develops. Taking guanfacine in the evening rather than the morning often reduces daytime sedation substantially. If sleepiness remains severe or is affecting school attendance and performance, contact your prescribing specialist to review the timing and dose.
Unlike stimulant medications, which can produce noticeable effects on the first day, guanfacine requires gradual dose titration over several weeks and its full therapeutic effect may not be apparent for 4–8 weeks after reaching the target dose. Patience during the titration process is essential; premature discontinuation due to perceived lack of early response is a common reason for unnecessary treatment failure.
Yes — guanfacine is frequently used as an adjunct to stimulant medications in children whose ADHD symptoms are not fully controlled by stimulants alone, or where stimulants produce troublesome side effects such as tics, insomnia, or anxiety that guanfacine can help manage. This combination should only be initiated and supervised by an ADHD specialist with appropriate monitoring of cardiovascular parameters.
If the missed dose is remembered on the same day, administer it. If it is not remembered until the next day, skip the missed dose and continue the usual schedule. Do not double up doses to compensate. If multiple doses are missed, contact your prescribing clinician before resuming, as restart protocols may be needed.